Table 1.
Participant characteristics of 75 MDR-TB patients randomised (1:1:1) to treatment with bedaquiline (n = 26), delamanid (n = 25), or both bedaquiline and delamanid (n = 24), plus standard of care.
| Variables | Bedaquiline | Delamanid | ||
|---|---|---|---|---|
| HIV-negative, n = 32 | HIV-positive, n = 18 | HIV-negative, n = 30 | HIV-positive, n = 19 | |
| Males (%) | 28 (80) | 14 (70) | 24 (73) | 16 (76) |
| Age, years | 34 (23–45) | 36.5 (28–42.5) | 30 (20–41) | 39 (30–43) |
| Race | ||||
| Black African | 10 | 15 | 7 | 14 |
| Mixed race | 20 | 3 | 20 | 5 |
| Hispanic | 2 | 0 | 3 | 0 |
| Albumin, g/L | 35 (29–37) | 32 (25.5–37) | 37 (32–40) | 33 (28–34) |
| Creatinine clearance, μmol/L | 95.3 (75.8–111.6) | 85.8 (75.4–97.0) | 84.8 (73.6–108.9) | 87.5 (65.7–110.2) |
| Weight, kg | 53.9 (50–61.2) | 56 (51.5–59.9) | 52.5 (50–58.8) | 54 (52.4–62) |
| BMI, kg/m2 | 19.2 (17.8–21.6) | 20.2 (19.0–21.9) | 19.1 (18.0–21.1) | 21.0 (18.8–22.3) |
| CD4 count cell/mm3 | — | 294 (167–572) | — | 256 (187–562) |
| Poor TB treatment outcomes, n | 2 | 1 | 2 | 1 |
Median with interquartile range is shown in brackets, where appropriate.
BMI = body mass index; MDR-TB = multidrug-resistant TB.